These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 32341410)

  • 1. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    Choucair K; Morand S; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
    Cancer Gene Ther; 2020 Dec; 27(12):841-853. PubMed ID: 32341410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
    Benitez JC; Recondo G; Rassy E; Mezquita L
    Q J Nucl Med Mol Imaging; 2020 Jun; 64(2):162-174. PubMed ID: 32107903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
    Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
    Valero C; Lee M; Hoen D; Weiss K; Kelly DW; Adusumilli PS; Paik PK; Plitas G; Ladanyi M; Postow MA; Ariyan CE; Shoushtari AN; Balachandran VP; Hakimi AA; Crago AM; Long Roche KC; Smith JJ; Ganly I; Wong RJ; Patel SG; Shah JP; Lee NY; Riaz N; Wang J; Zehir A; Berger MF; Chan TA; Seshan VE; Morris LGT
    Nat Commun; 2021 Feb; 12(1):729. PubMed ID: 33526794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Mutational Burden as a Biomarker of Immunotherapy Response: An Immunogram Approach in Onco-immunology.
    Ansari A; Ray SK; Sharma M; Rawal R; Singh P
    Curr Mol Med; 2024; 24(12):1461-1469. PubMed ID: 39420726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
    Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
    Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
    Jardim DL; Goodman A; de Melo Gagliato D; Kurzrock R
    Cancer Cell; 2021 Feb; 39(2):154-173. PubMed ID: 33125859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers.
    Halbert B; Einstein DJ
    Urology; 2021 Jan; 147():119-126. PubMed ID: 33137348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
    Chumsri S; Sokol ES; Soyano-Muller AE; Parrondo RD; Reynolds GA; Nassar A; Thompson EA
    J Natl Compr Canc Netw; 2020 May; 18(5):517-521. PubMed ID: 32380464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
    Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups.
    Hsiehchen D; Espinoza M; Valero C; Ahn C; Morris LGT
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
    Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
    Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.
    Cao JZ; Yao GS; Liu F; Tang YM; Li PJ; Feng ZH; Luo JH; Wei JH
    Aging (Albany NY); 2022 Mar; 14(6):2868-2879. PubMed ID: 35344507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
    Bagchi S; Yuan R; Engleman EG
    Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
    Yarchoan M; Albacker LA; Hopkins AC; Montesion M; Murugesan K; Vithayathil TT; Zaidi N; Azad NS; Laheru DA; Frampton GM; Jaffee EM
    JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30895946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.